Christopher Bunka, a director at Lexaria Bioscience Corp. ($LEXX), made two open market purchases of common shares totaling $25,241 in the last 365 days, with the most recent on July 30, 2025. These buys rank 3,583rd among nearly 5,000 insiders, well below the average purchase amount of $1.46 million across about 3.3 transactions. Bunka reported no open market sales in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 17, 2026 | Lexaria Bioscience Corp. | $LEXX | BUNKA CHRISTOPHER | Director | G | common shares | 100000 | $0.00 | 928,998.0000 | 24,887,446 | 9.72% | 0.40% |
| July 29, 2025 | Lexaria Bioscience Corp. | $LEXX | BUNKA CHRISTOPHER | Director | P | common shares | 15600 | $0.92 | 897,967.0000 | 0 | 1.77% | 0.00% |
| July 30, 2025 | Lexaria Bioscience Corp. | $LEXX | BUNKA CHRISTOPHER | Director | P | common shares | 11900 | $0.91 | 909,867.0000 | 0 | 1.33% | 0.00% |
| May 15, 2025 | Lexaria Bioscience Corp. | $LEXX | BUNKA CHRISTOPHER | Director | A | Stock Options | 11000 | $0.00 | 717,004.0000 | 0 | 1.56% | 0.00% |
| Jan. 7, 2025 | Lexaria Bioscience Corp. | $LEXX | BUNKA CHRISTOPHER | Director | A | Restricted Stock Award | 100000 | $0.00 | 373,543.0000 | 0 | 36.56% | 0.00% |
| April 26, 2024 | Lexaria Bioscience Corp. | $LEXX | BUNKA CHRISTOPHER | Chief Executive Officer | A | Stock Options | 49500 | $0.00 | 572,172.0000 | 0 | 9.47% | 0.00% |
| Oct. 26, 2023 | Lexaria Bioscience Corp. | $LEXX | BUNKA CHRISTOPHER | Chief Executive Officer | A | Stock Options | 30000 | $0.00 | 391,671.0000 | 0 | 8.29% | 0.00% |